​​​In a recent technical consultation hosted at Ágora in collaboration with the International Network for People Who Use Drugs (INPUD) and Students for Sensible Drug Policy (SSDP), experts gathered to address one of the most urgent challenges in global drug policy: the transition from stable botanical production to a toxic, synthetic drug supply. This shift has transformed the landscape of substance use, requiring a rigorous examination of both historical contexts and modern harm reduction strategies.

​

The three chapters of the opium story

​

Benjamin R. Siegel, a historian of global commodity economics, framed the current crisis through three historical "chapters" that illustrate how political and commercial choices narrowed the options available for people experiencing pain:

​

Technical isolation and substitution: Starting with the isolation of morphine in 1817, chemists began breaking opium down into its constituent alkaloids to create new compounds such as heroin and oxycodone. By 1959, the synthesis of fentanyl—which is 100 times more potent than morphine—marked a peak in the quest to sever global dependence on the poppy plant.

​

Dismantling agricultural infrastructure: In the late 20th century, international policy shifted toward dismantling the global agricultural systems that had stabilized the pharmaceutical opioid trade. This led to the displacement of traditional farming families in Turkey and India, effectively severing the link between agricultural labor and state oversight.

​

The rise of the synthetic surge: As the legal supply was tightened and global infrastructure collapsed, the demand for opioids was met by the aggressive marketing of synthetics. When heroin became adulterated and displaced by fentanyl, the result was the toxic drug supply currently driving mass overdose deaths.

​

Route switching: the transition from injecting to smoking

​

The reality of this toxic supply is notably visible in British Columbia, Canada, where Dr. Jade Boyd has documented a significant shift in consumption methods. Since the declaration of a public health emergency in 2016, there has been a steady transition from injecting to smoking unregulated opioids.

​

In 2025, data indicated that 65% of overdose deaths in British Columbia were related to smoking, compared to only 9% related to injecting. Despite this trend, most harm reduction supports remain focused primarily on injection. Research into why individuals switch to smoking reveals complex motivations:

Overdose risk management: Many individuals perceive smoking as a method of maintaining greater control, allowing them to take smaller "hits" of highly potent substances to gauge the effect.

​

Protection against violence: For women and marginalized genders, smoking is often seen as a way to avoid the "blackouts" associated with adulterants like benzodiazepines, thereby reducing the risk of gender-based violence.

Autonomy and social connection: Smoking allows for greater independence, as it does not require the assistance often needed for injection, and it is viewed as a more social activity.

 

The need for innovative harm reduction

​

The current crisis demands a transition beyond traditional medicalized settings. Experts at the consultation highlighted several key areas for policy innovation:

Expanding sanctioned smoking spaces: There is a severe lack of indoor and outdoor spaces where individuals can safely smoke substances under supervision.

Advanced drug checking: Expanding access to technologies that can identify adulterants, such as benzodiazepines or tranquilizers, is crucial for informed use.

Supply distribution: Increasing the availability of sterile smoking equipment, such as heat-resistant pipes and foils, is a necessary step in reducing health harms.

Prescribed alternatives: Providing access to pharmaceutical-grade, smokable alternatives to the unregulated supply could meet the needs of those at the highest risk.

 

Looking forward: policy and science

​

While some regions have begun exploring the legal medical use of substances like psilocybin and MDMA, much of the world remains caught in a cycle of prohibition and rising toxicity. In cities like Vienna, researchers find that progress often relies on scientific and psychiatric frameworks to justify the implementation of new services.

​

Ultimately, the transition from botanical to synthetic drugs is not merely a chemical shift but a result of historical political compromises. To address the challenges of the current global system, future policies must be built on an interrogation of inherited categories and a commitment to centering the expertise of those with living experience